Brief Report on Eiger BioPharmaceuticals Stock

Shares of Healthcare sector company Eiger BioPharmaceuticals moved -69.3% today, and are now trading at a price of $1.18. The small-cap stock's daily volume was 2,412,969 compared to its average volume of 337,326. The S&P 500 index returned a 0.3% performance.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. The company is based in Palo Alto and has 54 full time employees. Its market capitalization is $52,007,672.

4 analysts are following Eiger BioPharmaceuticals and have set target prices ranging from $20 to $48 per share. On average, they have given the company a rating of strong buy. At today's prices, EIGR is trading -96.22% away from its average analyst target price of $31.25 per share.

Over the last year, EIGR shares have gone down by -37.2%, which represents a difference of -21.4% when compared to the S&P 500. The stock's 52 week high is $10.02 per share and its 52 week low is $1.18. Eiger BioPharmaceuticals has averaged free cash flows of $-60,478,000.0 over the last four years, with a mean growth rate of -20.5%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.